Bain uses cookies to improve functionality and performance of this site. More information can be found in our Privacy Policy. By continuing to browse this site, you consent to the use of cookies.

We have limited Portuguese content available. View Portuguese content.

S&P Global

China FDA's Sovaldi nod could usher in more fast track approvals

China FDA's Sovaldi nod could usher in more fast track approvals

  • setembro 29, 2017
  • min read

S&P Global

China FDA's Sovaldi nod could usher in more fast track approvals

Due to the Chinese government's recent fast tracking of certain new drugs' approval, more and more international foreign pharma companies will likely try to file applications with the China FDA, according to Phil Leung, a partner with Bain & Company in Shanghai.

Go to S&P Global

Subscription required